284 related articles for article (PubMed ID: 27908281)
1. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
Rawson NS
Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.
Richter T; Janoudi G; Amegatse W; Nester-Parr S
Orphanet J Rare Dis; 2018 Feb; 13(1):15. PubMed ID: 29386040
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
[TBL] [Abstract][Full Text] [Related]
5. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
McCormick JI; Berescu LD; Tadros N
Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
[TBL] [Abstract][Full Text] [Related]
6. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
[TBL] [Abstract][Full Text] [Related]
7. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
8. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
[TBL] [Abstract][Full Text] [Related]
9. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC
Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers AJN; Regier DA; Peacock SJ
Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
[TBL] [Abstract][Full Text] [Related]
11. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
Stafinski T; Glennie J; Young A; Menon D
Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
[TBL] [Abstract][Full Text] [Related]
12. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
13. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
Binder L; Ghadban M; Sit C; Barnard K
Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
[TBL] [Abstract][Full Text] [Related]
14. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
15. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
Rawson NSB
Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
[TBL] [Abstract][Full Text] [Related]
16. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
Graili P
Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
[TBL] [Abstract][Full Text] [Related]
17. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
Fontrier AM; Kanavos P
Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379
[TBL] [Abstract][Full Text] [Related]
18. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Menon D; Clark D; Stafinski T
Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
20. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
Szabo SM; Hawkins NS; Germeni E
Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
